Keywords: Kyowa Hakko Kirin, Pegfilgrastim, Ph III, Regulatory filing, Japan, Breast cancer

Kyowa Hakko set to file for pegfilgrastim approval in Japan following strong Ph III data

Article | 28 January 2013

Print This

Mid-size Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) on Friday released positive top-line results of two Phase III trials of KRN125 ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in